Shanghai Pharmaceuticals Holdings and Johnson & Johnson Enter Strategic Partnership for CNS Long-Acting Injectables

People's Finance News, April 16th: On April 15th, Shanghai Pharmaceutical Co., Ltd. announced a nationwide full-channel strategic cooperation with Johnson & Johnson on long-acting injections in the psychiatric CNS field. Link Health, under Shanghai Pharmaceutical, signed an exclusive market promotion agreement with Johnson & Johnson to fully take charge of the long-acting injection for schizophrenia, Xeplion, in China.®, Shantoda®Heshan Jiuda®Market promotion work.